journal
MENU ▼
Read by QxMD icon Read
search

Journal of Ocular Pharmacology and Therapeutics

journal
https://www.readbyqxmd.com/read/28632458/aquaporins-novel-targets-for-age-related-ocular-disorders
#1
Rajkumar Patil, Haishan Wang, Najam A Sharif, Alok Mitra
Aquaporins (AQPs), a large family of membrane protein channels that facilitate transport of water and other small solutes, play important roles in physiological functions and human diseases. Up till now, 13 types of AQPs, numbered 0 through 12, have been identified in various mammalian tissues. Homologous genes for AQPs in amphibians, insects, and bacteria highlight the evolutionary conservation and, thus, the importance of these membrane channels. Many members of the AQP family are expressed in the eye. AQP1, which is a water-selective channel, is expressed in the anterior chamber (cornea, ciliary body, trabecular meshwork) and posterior chamber (retina and microvessels in choroid), controlling the fluid homeostasis in the eye...
June 20, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28618236/eyes-on-new-product-development
#2
Gary D Novack
No abstract text is available yet for this article.
June 15, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28609185/discovery-and-preclinical-development-of-netarsudil-a-novel-ocular-hypotensive-agent-for-the-treatment-of-glaucoma
#3
Cheng-Wen Lin, Bryan Sherman, Lori A Moore, Carmen L Laethem, Da-Wen Lu, Padmanabhan P Pattabiraman, Ponugoti Vasantha Rao, Mitchell A deLong, Casey C Kopczynski
PURPOSE: Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is presented herein. METHODS: The kinase inhibitory activity of netarsudil was compared to its esterase metabolite, netarsudil-M1, and 3 other ROCK inhibitors using a commercially available kinase assay kit...
June 13, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28609158/is-the-eye-an-extension-of-the-brain-in-central-nervous-system-disease
#4
Lies De Groef, Maria Francesca Cordeiro
No abstract text is available yet for this article.
June 13, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28605219/retraction-of-azithromycin-1-5-ophthalmic-solution-for-blepharitis-treatment-comparison-of-14-versus-30-day-treatment-doi-10-1089-jop-2015-0099
#5
(no author information available yet)
No abstract text is available yet for this article.
June 12, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28598703/in-silico-ocular-pharmacokinetic-modeling-delivery-of-topical-fk962-to-retina
#6
Ayumi Mori, Chiho Yabuta, Yayoi Kishimoto, Seiko Kozai, Akira Ohtori, Thomas R Shearer, Mitsuyoshi Azuma
PURPOSES: To establish the in silico ocular pharmacokinetic modeling for eye drops, and to simulate the dose regimen for FK962 in human choroid/retinal diseases. METHODS: Pharmacokinetics for FK962 in vivo was performed by a single instillation of drops containing 0.1% (14)C-FK962 in rabbit eyes. Permeation of FK962 across the cornea, sclera, and choroid/retina was measured in vitro. Neurite elongation by FK962 was measured in cultured rat retinal ganglion cells...
June 9, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28590790/the-effect-of-ascorbic-acid-vitamin-c-on-transepithelial-corneal-cross-linking-in-rabbits
#7
Mustafa Koc, Basak Bostanci, Ozlem Ozbas Demirel, Feyza Genc, Kemal Tekin, Yaran Koban, Aylin Sepici Dincel, Murat Sen, Pelin Yilmazbas
PURPOSE: To evaluate the effects of ascorbic acid (vitamin C), the main antioxidant agent in the cornea on transepithelial corneal cross-linking (CXL) where the main mechanism is oxidation. METHODS: Twenty eyes of 20 rabbits were divided into 3 groups: Group 1 (7 eyes) had transepithelial corneal CXL after being fed with normal diet; Group 2 (7 eyes) had corneal CXL after once-daily subcutaneous injections of 200 mg of ascorbic acid in addition to normal diet; and the control group (6 eyes) was fed with normal diet but did not have corneal CXL performed...
June 7, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/26717146/retracted-azithromycin-1-5-ophthalmic-solution-for-blepharitis-treatment-comparison-of-14-versus-30-day-treatment
#8
Yesim Altay, Gulizar Demirok, Ozgur Balta, Hulya Bolu
The online-ahead-of-print published article, "Azithromycin 1.5% Ophthalmic Solution for Blepharitis Treatment: Comparison of 14- Versus 30-Day Treatment," by Altay Yesim, Demirok Gulizar, Balta Ozgur, and Bolu Hulya (DOI: 10.1089/jop.2015.0099) is being officially retracted from Journal of Ocular Pharmacology and Therapeutics (JOPT) due to post-publication authorship disputes and the discovery of simultaneous submission to both JOPT and the International Journal of Ophthalmology, which is a violation of the proper protocols of peer review...
June 5, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28557667/real-life-experience-with-aflibercept-and-ranibizumab-in-the-treatment-of-newly-diagnosed-neovascular-age-related-macular-degeneration-over-24-months
#9
Justus G Garweg, Christin Gerhardt, Laurent Kodjikian, Isabel B Pfister
PURPOSE: Comparative data appertaining to the long-term effects of Aflibercept or Ranibizumab in newly diagnosed cases of neovascular age-related macular degeneration (nAMD) over follow-up periods exceeding 12 months in clinical routine are scarce. METHODS: In this retrospective comparative analysis, a case series of patients with treatment-naïve nAMD and requiring anti-vascular endothelial growth factor (VEGF) therapy in a routine clinical setting were treated with either Aflibercept [Afl (n = 106)] or Ranibizumab [Ran (n = 47)]...
May 30, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28557655/tear-film-stability-in-sj%C3%A3-gren-syndrome-patients-treated-with-hyaluronic-acid-versus-crosslinked-hyaluronic-acid-based-eye-drops
#10
Carlo Cagini, Giovanni Torroni, Tito Fiore, Alessio Cerquaglia, Marco Lupidi, Pasquale Aragona, Barbara Iaccheri
PURPOSE: To compare the stability of the tear film after instillation of eye drops containing hyaluronic acid (HA) or crosslinked hyaluronic acid (CLHA)-based in patients with Sjögren syndrome-related dry eye (SSDE). METHODS: Forty subjects were included in this study and were divided into 2 groups: the first group (control group) consisted of 20 healthy volunteers; the second group (study group) constituted of 20 suffering from SSDE; before and 5, 30, and 60 min after instillation of eye drops the surface regularity index (SRI) and surface asymmetry index (SAI) were registered...
May 30, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28557602/systemic-steroid-sparing-effect-of-intravitreal-dexamethasone-implant-in-chronic-noninfectious-uveitic-macular-edema
#11
Claudia Fabiani, Antonio Vitale, Giacomo Emmi, Giuseppe Lopalco, Lorenzo Vannozzi, Daniela Bacherini, Silvana Guerriero, Rosa Anna Favale, Fiorella Fusco, Rossella Franceschini, Bruno Frediani, Florenzo Iannone, Mauro Galeazzi, Gian Marco Tosi, Luca Cantarini
PURPOSE: To evaluate the effectiveness and the systemic corticosteroid sparing effect of a single intravitreal dexamethasone (DEX) implant in patients with chronic noninfectious uveitic macular edema (UME). METHODS: Data from 22 eyes treated with DEX implant for UME related to systemic or ocular-confined noninfectious diseases were retrospectively analyzed. RESULTS: The mean systemic prednisone (or equivalent) dosage significantly decreased at 3- and 6-month follow-up evaluations compared to baseline (P = 0...
May 30, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28514197/change-of-serum-igg4-in-patients-with-ocular-adnexal-marginal-zone-b-cell-lymphoma-associated-with-igg4-related-ophthalmic-disease-after-treatment
#12
Yuan-Hung Wu, Lei-Chi Wang, Sang-Hue Yen, Wei-Kuang Yu, Shu-Ching Kao, Hui-Chuan Kau, Chieh-Chih Tsai, Catherine Jui-Ling Liu
PURPOSE: To investigate the change of serum IgG4 concentrations correlated with clinical evolution in patients with ocular adnexal marginal zone B cell lymphoma associated with IgG4-related ophthalmic disease (IgG4-ROD). METHODS: Three consecutive patients with histopathologically confirmed ocular adnexal marginal zone B cell lymphoma associated with IgG4-ROD were evaluated. Two patients received radiotherapy and 1 patient received steroid therapy. Treatment outcome was evaluated by clinical symptoms, radiologic examination, and change of serum IgG4 level in these patients...
May 17, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28445077/effect-of-epiretinal-membranes-on-antivascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration
#13
Han Joo Cho, Jae Min Kim, Hyoung Seok Kim, Dong Won Lee, Chul Gu Kim, Jong Woo Kim
PURPOSE: To evaluate the effect of epiretinal membranes (ERMs), detected with spectral-domain optical coherence tomography (SD-OCT), on the outcome of antivascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD). METHODS: A total of 434 eyes with treatment-naive nAMD were retrospectively included and analyzed. All patients were administered an initial series of 3 monthly loading injections of ranibizumab or aflibercept, followed by further injections as required...
April 26, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28414592/understanding-the-presence-and-roles-of-ap4a-diadenosine-tetraphosphate-in-the-eye
#14
Almudena Crooke, Ana Guzman-Aranguez, Gonzalo Carracedo, Maria J Perez de Lara, Jesus Pintor
Diadenosine tetraphosphate abbreviated Ap4A is a naturally occurring dinucleotide, which is present in most of the ocular fluids. Due to its intrinsic resistance to enzyme degradation compared to mononucleotides, this molecule can exhibit profound actions on ocular tissues, including the ocular surface, ciliary body, trabecular meshwork, and probably the retina. The actions of Ap4A are mostly carried out by P2Y2 receptors, but the participation of P2X2 and P2Y6 in processes such as the regulation of intraocular pressure (IOP), together with the P2Y2, is pivotal...
April 17, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28402720/insulin-like-growth-factor-binding-protein-related-protein-1-inhibit-retinal-neovascularization-in-the-mouse-model-of-oxygen-induced-retinopathy
#15
Ping Zhang, Hong Wang, Hui Cao, Xun Xu, Tao Sun
PURPOSE: To explore the inhibitory effect of insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) on retinal angiogenesis and its underlying molecular mechanisms in the mouse model of oxygen-induced retinopathy (OIR). METHODS: C57BL/6J mice were classified into three groups as control group, OIR nonintervention group, and OIR intervention group. Postnatal day 12 (P12) mice in OIR intervention group were received recombinant mouse IGFBP-rP1 (50, 100, and 200 ng/mL) intravitreal injection...
April 12, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28384009/incidence-and-timing-of-the-first-recurrence-in-neovascular-age-related-macular-degeneration-comparison-between-ranibizumab-and-aflibercept
#16
Jae Hui Kim, Young Suk Chang, Dong Won Lee, Chul Gu Kim, Jong Woo Kim
PURPOSE: To compare the incidence and timing of first recurrence between patients who were treated with ranibizumab and aflibercept in neovascular age-related macular degeneration (AMD). METHODS: This retrospective study included 120 patients who received the diagnosis of treatment-naive typical neovascular AMD or polypoidal choroidal vasculopathy (PCV) and were treated using either ranibizumab (n = 73) or aflibercept (n = 47). Recurrence within 10 months of the third injection was compared between the 2 treatment groups...
April 6, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375791/intravitreal-dexamethasone-implant-for-treatment-of-serous-macular-detachment-in-central-retinal-vein-occlusion
#17
Ahmet Elbay, Hakan Ozdemir, Arif Koytak, Arif Melikov
PURPOSE: To evaluate the effect of intravitreal dexamethasone implant (Ozurdex) treatment on serous macular detachment (SMD) in patients with nonischemic central retinal vein occlusion (CRVO). METHODS: Retrospective, interventional, noncomparative case series was conducted. Twenty-four eyes of 24 patients with macular edema (ME) and SMD secondary to nonischemic CRVO made up the study population. Patients who had received intravitreal triamcinolone and/or antivascular endothelial growth factor treatment and/or had undergone retinal photocoagulation were excluded from the study...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375789/the-effect-of-tear-supplementation-with-0-15-preservative-free-zinc-hyaluronate-on-ocular-surface-sensations-in-patients-with-dry-eye
#18
Kristóf Perényi, Lóránt Dienes, Anna Kornafeld, Balázs Kovács, Huba J Kiss, Zsuzsanna Szepessy, Zoltán Z Nagy, Árpád Barsi, M Carmen Acosta, Juana Gallar, Illés Kovács
PURPOSE: To evaluate the effect of tear supplementation with preservative free 0.15% zinc-hyaluronate on ocular surface sensations and corneal sensitivity in dry eye patients. METHODS: Ocular surface sensations were assessed using the ocular surface disease index (OSDI) questionnaire and by recording ocular sensations during forced blinking in parallel with noninvasive tear film breakup time measurement in 20 eyes of 20 dry eye patients. Corneal sensitivity thresholds to selective stimulation of corneal mechano-, thermal- and chemical receptors were measured using the Belmonte gas esthesiometer...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375788/real-world-experience-with-half-time-versus-half-dose-photodynamic-therapy-in-chronic-central-serous-chorioretinopathy
#19
Shu-Yen Peng, Chi-Chun Lai, Nan-Kai Wang, Wei-Chi Wu, Yih-Shiou Hwang, Kuan-Jen Chen, Lee-Jen Chen, Shawn Tsai, Wei-Chun Chan, Laura Liu, Ling Yeung
PURPOSE: To evaluate the real-world experience with half-time photodynamic therapy (PDT) versus half-dose PDT for chronic central serous chorioretinopathy (CSC). METHODS: This multicenter retrospective study enrolled patients who received half-time PDT (with irradiation time shortened to 42 s) or half-dose PDT (with the dosage of verteporfin reduced to 3 mg/m(2)) for chronic CSC and who were followed up for ≧12 months. The success rate, central subfield retinal thickness (CST), and best-corrected visual acuity (BCVA) were documented in each group of patients...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28537766/pirfenidone-induces-g1-arrest-in-human-tenon-s-fibroblasts-in-vitro-involving-akt-and-mapk-signaling-pathways
#20
Xiujuan Guo, Yangfan Yang, Liling Liu, Xiaoan Liu, Jiangang Xu, Kaili Wu, Minbin Yu
PURPOSE: To investigate the underlying mechanism by which pirfenidone blocks the transition from the G1 to S phase in primary human Tenon's fibroblasts. METHODS: Primary human Tenon's fibroblasts were characterized by immunocytofluorescence staining with vimentin, fibroblast surface protein, and cytokeratin. After treating Tenon's fibroblasts with pirfenidone under proliferation conditions (10% fetal bovine serum), cell proliferation was measured using a WST-1 assay...
June 2017: Journal of Ocular Pharmacology and Therapeutics
journal
journal
32321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"